Inhibrx Biosciences, Inc.INBXNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
25.57%
↑ 131% above average
Average (30q)
11.09%
Historical baseline
Range
High:127.88%
Low:-43.47%
Volatility
1544.8%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 25.57% |
| Q2 2025 | -39.62% |
| Q1 2025 | 10.52% |
| Q4 2024 | -12.73% |
| Q3 2024 | -43.47% |
| Q2 2024 | 6.35% |
| Q1 2024 | -22.29% |
| Q4 2023 | 115.04% |
| Q3 2023 | 12.38% |
| Q2 2023 | -9.42% |
| Q1 2023 | 22.77% |
| Q4 2022 | 22.13% |
| Q3 2022 | -16.63% |
| Q2 2022 | 20.13% |
| Q1 2022 | 33.74% |
| Q4 2021 | 0.70% |
| Q3 2021 | 3.26% |
| Q2 2021 | 8.91% |
| Q1 2021 | -6.96% |
| Q4 2020 | -10.93% |
| Q3 2020 | 4.55% |
| Q2 2020 | 11.51% |
| Q1 2020 | 38.53% |
| Q4 2019 | -3.93% |
| Q3 2019 | 5.02% |
| Q2 2019 | 14.15% |
| Q1 2019 | 127.88% |
| Q4 2018 | 0.00% |
| Q2 2018 | -21.19% |
| Q1 2018 | 47.88% |
| Q4 2017 | 0.00% |